THYROID CANCERS

General Cancer

Alexander Drilon, MD, discusses findings from the phase I LIBRETTO-001 study on the safety of LOXO-292 for the treatment of patients with RET-altered cancers.

The highly-selective RET inhibitor LOXO-292 induced an objective response rate of 77% for patients with RET fusion-positive non–small cell lung cancer, according to findings from the phase I LIBRETTO-001 study presented at the 2018 ASCO Annual Meeting.

The combination of&nbsp;dabrafenib (Tafinlar) and&nbsp;trametinib (Mekinist) has been approved by the FDA&nbsp;for the treatment of patients with unresectable or metastatic<em> BRAF</em> V600E&ndash;positive anaplastic thyroid cancer.&nbsp;